



20 November 2007

CathRx Receives CE Marking for Formable Stylet for Cardiac Diagnostic Catheters

CathRx Ltd (ASX code: CXD) announced today that it has received CE marking for its formable stylet which can be used with its cardiac diagnostic catheters. This permits CathRx to sell these devices into the European Union.

The CE marking was received from TÜV SÜD, a European Notified Body. The formable stylet is part of the CathRx modular range of stylets that can be used with its catheters that are used for the diagnosis of abnormal rhythms of the heart called cardiac arrhythmias.

The formable stylet is a novel design that allows the clinician to fashion the end of the stylet, and therefore the catheter, to any of the shapes of fixed curve catheters currently on the market. It can do the work of multiple products in one.

This stylet together with the range of deflectable versions and the 4 and 10 electrode catheters, will be the focus of the CathRx market launch in Europe. The products to be initially sold in Europe are still subject to the approval by TÜV SÜD of one additional addenda relating to a change in cable source to one manufactured by CathRx which has increased radio-opacity of the electrodes. The approval of this addenda is expected within the next four weeks.

Neil Anderson commented, "This CE marking for the formable stylet is another key step in our product strategy. We are now only waiting for the last change addenda to be approved for the catheters prior to the next stage of our launch, however our launch activities are already underway with the building of product inventory."

Ends

For additional information please contact: Denis Hanley
Phone: 04 1844 5021
Email: denishanley@cathrx.com

About CathRx

CathRx is developing catheters for the diagnosis and treatment of cardiac arrhythmias which are irregular heart pumping rhythms caused by problems with the conductive pathways of the heart. These arrhythmias are diagnosed and in some cases cured by cardiac catheters creating therapeutic lesions on the wall of the heart designed to restore the conductive pathway to its normal rhythm.

CathRx has developed a novel way of manufacturing these catheters. It plans to introduce its products first to the least complex clinical procedures in the right side of the heart and then

progressively to address the more difficult clinical procedures on the left side of the heart such as atrial fibrillation. The goal in all cases is to provide the clinician with customised tools that are better suited to creating the required sensing and lesions for a specific patient in the least time possible. At the same time these catheters can provide cost efficiencies for hospitals when compared to current methods of treatment.